Brent Zanke
Gründer bei ArcticDX, Inc.
Profil
Brent Zanke is the founder of ArcticDX, Inc. where he holds the title of Director starting in 2006.
Dr. Zanke is also the founder of CTRL Therapeutics, Inc. Dr. Zanke's former job was as Director at Cross Cancer Institute.
Dr. Zanke earned a doctorate degree from the University of Toronto in 1993 and another doctorate degree from the University of Manitoba in 1983.
Aktive Positionen von Brent Zanke
| Unternehmen | Position | Beginn |
|---|---|---|
ArcticDX, Inc.
 ArcticDX, Inc. Medical/Nursing ServicesHealth Services ArcticDX, Inc. designs molecular diagnostic testing services. It provides age-related macular degeneration progression and AMD pharmacogenetics which is used to optimize therapeutic outcomes, determine the appropriate dose for a patient, and avoid harmful effects. The company was founded by Brent Zanke and Gregory C. Hines in 2005 and is headquartered in Toronto, Canada. | Gründer | 10.06.2010 |
Ehemalige bekannte Positionen von Brent Zanke
| Unternehmen | Position | Ende |
|---|---|---|
CTRL Therapeutics, Inc.
 CTRL Therapeutics, Inc. BiotechnologyHealth Technology CTRL Therapeutics, Inc. engages in the development of liquid biopsy technology. It focuses on the phenotypic properties of tumors and metastatic disease. The company was founded by Brent Zanke and Shana O. Kelley and is headquartered in Toronto, Canada. | Vorstandsvorsitzender | - |
| Cross Cancer Institute | Direktor/Vorstandsmitglied | - |
Ausbildung von Brent Zanke
| University of Toronto | Doctorate Degree |
| University of Manitoba | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
ArcticDX, Inc.
ArcticDX, Inc. Medical/Nursing ServicesHealth Services ArcticDX, Inc. designs molecular diagnostic testing services. It provides age-related macular degeneration progression and AMD pharmacogenetics which is used to optimize therapeutic outcomes, determine the appropriate dose for a patient, and avoid harmful effects. The company was founded by Brent Zanke and Gregory C. Hines in 2005 and is headquartered in Toronto, Canada. | Health Services |
| Cross Cancer Institute | |
CTRL Therapeutics, Inc.
CTRL Therapeutics, Inc. BiotechnologyHealth Technology CTRL Therapeutics, Inc. engages in the development of liquid biopsy technology. It focuses on the phenotypic properties of tumors and metastatic disease. The company was founded by Brent Zanke and Shana O. Kelley and is headquartered in Toronto, Canada. | Health Technology |
